Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Ajanta Pharma Q1 net...

    Ajanta Pharma Q1 net up 12 percent at Rs 106 crore

    Written by Ruby Khatun Khatun Published On 2018-08-01T10:15:11+05:30  |  Updated On 1 Aug 2018 10:15 AM IST
    Ajanta Pharma Q1 net up 12 percent at Rs 106 crore

    New Delhi: Ajanta Pharma reported 11.60 percent rise in consolidated net profit at Rs 105.79 crore for the June quarter on account of robust sales in branded generic business.


    The company had posted a net profit of Rs 94.79 crore in the year-ago period, Ajanta Pharma said in a BSE filing.


    Consolidated income from operations stood at Rs 510.99 crore for the reported quarter. It was Rs 473.12 crore for the same period a year ago.

    "We are pleased with our June quarter performance which is in line with our expectations. Branded generic business in India and Export markets posted healthy growths," MD Yogesh Agrawal said.

    Despite challenging pricing environment in the US, the company has posted healthy growth for the quarter, he added.

    "Going forward, branded generic business in India and Emerging Markets, and generic business in the US will be key focus markets for us," Agrawal said.

    Ajanta Pharmabranded generic businessfinancial reultsJune quarternet profitQ1Yogesh Agrawal
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok